J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA.
J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA; Department of Biomedical Engineering, University of California, Davis, CA 95616, USA.
Adv Drug Deliv Rev. 2024 Jul;210:115329. doi: 10.1016/j.addr.2024.115329. Epub 2024 May 8.
Autoimmune diseases are burdensome conditions that affect a significant fraction of the global population. The hallmark of autoimmune disease is a host's immune system being licensed to attack its tissues based on specific antigens. There are no cures for autoimmune diseases. The current clinical standard for treating autoimmune diseases is the administration of immunosuppressants, which weaken the immune system and reduce auto-inflammatory responses. However, people living with autoimmune diseases are subject to toxicity, fail to mount a sufficient immune response to protect against pathogens, and are more likely to develop infections. Therefore, there is a concerted effort to develop more effective means of targeting immunomodulatory therapies to antigen-presenting cells, which are involved in modulating the immune responses to specific antigens. In this review, we highlight approaches that are currently in development to target antigen-presenting cells and improve therapeutic outcomes in autoimmune diseases.
自身免疫性疾病是一种负担沉重的疾病，影响了全球很大一部分人口。自身免疫性疾病的标志是宿主的免疫系统被授权根据特定抗原攻击其组织。目前还没有治愈自身免疫性疾病的方法。治疗自身免疫性疾病的当前临床标准是使用免疫抑制剂，这些抑制剂削弱免疫系统并减少自身炎症反应。然而，患有自身免疫性疾病的人会受到毒性影响，无法对病原体产生足够的免疫反应，并且更容易感染。因此，人们正在努力开发更有效的方法来针对抗原呈递细胞进行免疫调节治疗，这些细胞参与调节对特定抗原的免疫反应。在这篇综述中，我们重点介绍了目前正在开发的针对抗原呈递细胞的方法，以改善自身免疫性疾病的治疗效果。
